The Impact of vitamin B12 supplementation on the efficacy of conventional drug in the management of pcos patient

Not Applicable

Conditions: Health Condition 1: null- patient will get vitamin B 12 supplement along with standard medications

Registration Number: CTRI/2018/06/014570

Lead Sponsor: AIIMS Research Section

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Open to Recruitment

Sex: Not specified

Target Recruitment: 0

Inclusion Criteria

The details of menstrual history will include age of menarche ,regularity,duration,dysamenorrhea,flow and number of menstrual cycles per year.The history of weight gain, obesity, infertility,unwanted hair growth,acne vulgaris,etc will be recorded as per a prediagnosed performa. A pedigree will be made to note family history of hirusitism, infertility, hypertention,menstrual disorders,known diabetes mellitus or glucose intolerence, CAD and obesity at least in three generations. The diagnosis of PCOS will be based on the presence of two out of three following features with the exclusion of other etiologies of androgen excess and anovulatory infertility. these features include.

1.clinical/ biochemical science of androgenism

2.oligo or chronic anovulation.

3. polycysitic ovaries on transabdominal ultrasonography.

Exclusion Criteria

Diabetes mellitus/Hypertension/COPD / chronic lung disease/ Hypothyriod

Pregnancy and lactation

Drugs (steroids, lithium, NSAIDs, ACE inhibitors, statins)

Patients who refuse consent

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
a) To compare biochemical and hormonal parameters between vegetarian and non vegetarian <br/ ><br>(b) To compare Clinical parameters (menstrual cycles, hirsutism score, testosterone levels) after treatment with levothyroxine and life style modification. <br/ ><br>(c) to evaluate the impact of vit-B 12 supplementation on the efficacy of conventional drugs in the management of women with PCOSTimepoint: 0,3 and 6 months

Secondary Outcome Measures